{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:28:39Z","timestamp":1753522119894},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Treatment of spondyloarthritis (SpA) has greatly improved in the biopharmaceutical era. These compounds, primarily tumor necrosis factor inhibitors, are effective, but some patients may show poor response, sometimes due to the presence of antidrug antibodies (ADAs). In some instances, clinicians may increase or taper the dose, depending on the clinical response. Besides the current clinical practice, a tailored strategy based on drug monitoring is emerging as a way to improve the use of these drugs. However, the relevance of this therapeutic drug monitoring of biopharmaceuticals for SpA is still unknown. In this literature review, we examined the most relevant articles dealing with the concentration\u2013response relation, ADA detection, and pharmacokinetics in SpA treated with biopharmaceuticals. ADAs were associated with low or undetectable concentration of monoclonal antibodies. The relation between drug concentration and clinical response in SpA is debated, some studies showing an association and others not. Therefore, therapeutic drug monitoring of biopharmaceuticals for SpA requires a better understanding of the association among the pharmacokinetics, pharmacodynamics, and immunogenicity of these drugs.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000400","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T15:55:47Z","timestamp":1491407747000},"page":"360-363","source":"Crossref","is-referenced-by-count":8,"title":["Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis"],"prefix":"10.1097","volume":"39","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Medina","sequence":"first","affiliation":[{"name":"Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chamaida","family":"Plasencia","sequence":"additional","affiliation":[{"name":"Rheumatology Department and Health Research Institute (Idipaz), Hospital Universitario de La Paz, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[{"name":"Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[{"name":"Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[{"name":"Rheumatology Department and Health Research Institute (Idipaz), Hospital Universitario de La Paz, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Mulleman","sequence":"additional","affiliation":[{"name":"Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbspin.2014.08.003","article-title":"The IL-23\/Th 17 pathway in spondyloarthritis: the royal road?","volume":"82","author":"Wendling","year":"2015","journal-title":"Joint Bone Spine."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/FTD.0000000000000385","article-title":"Biopharmaceuticals: reference products and biosimilars to treat inflammatory diseases","volume":"39","author":"Gils","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3899\/jrheum.150389","article-title":"Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study","volume":"42","author":"Heinonen","year":"2015","journal-title":"J Rheumatol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Immunogenicity of therapeutic antibodies: monitoring anti-drug antibodies in a clinical context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Compan","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/rheumatology\/kei085","article-title":"Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study","volume":"44","author":"Collantes-Estevez","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/imt.12.114","article-title":"Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine","volume":"4","author":"Bendtzen","year":"2012","journal-title":"Immunotherapy"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FTD.0000000000000410","article-title":"Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases","volume":"39","author":"Paintaud","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","article-title":"Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar3386","article-title":"Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases","volume":"13","author":"Ducourau","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24275","article-title":"Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study","volume":"61","author":"Krzysiek","year":"2009","journal-title":"Arthritis Rheum."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar3350","article-title":"Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study","volume":"13","author":"Mulleman","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2011-200828","article-title":"Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab","volume":"71","author":"Plasencia","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2125.2011.04050.x","article-title":"Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis","volume":"73","author":"Ternant","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1136\/annrheumdis-2014-205213","article-title":"Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up","volume":"74","author":"Kneepkens","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2013-204185","article-title":"Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up","volume":"74","author":"Kneepkens","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar4675","article-title":"Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation","volume":"16","author":"Paramarta","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/ard.2009.108787","article-title":"Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis","volume":"69","author":"van Kuijk","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1136\/annrheumdis-2014-205554","article-title":"Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up","volume":"73","author":"Vogelzang","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/ard.2009.109702","article-title":"Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3899\/jrheum.140685","article-title":"Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis","volume":"42","author":"Zisapel","year":"2015","journal-title":"J Rheumatol."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","article-title":"Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","article-title":"Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases","volume":"32","author":"Mok","year":"2013","journal-title":"Clin Rheumatol."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4258","article-title":"The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients","volume":"15","author":"Plasencia","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.2006.057745","article-title":"Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3899\/jrheum.141128","article-title":"Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity","volume":"42","author":"Plasencia","year":"2015","journal-title":"J Rheumatol."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/03009742.2015.1114666","article-title":"Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients","volume":"45","author":"Marsman","year":"2016","journal-title":"Scand J Rheumatol."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/FTD.0b013e318224f83d","article-title":"Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study","volume":"33","author":"M\u00e9ric","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/FTD.0000000000000394","article-title":"Current practice for therapeutic drug monitoring of biopharmaceuticals in inflammatory bowel diseases","volume":"39","author":"Detrez","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/FTD.0000000000000400","article-title":"Current practice for therapeutic drug monitoring of biopharmaceuticals in rheumatoid arthritis patients","volume":"39","author":"Medina","year":"2017","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:11:43Z","timestamp":1692051103000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000400","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}